Is Thymosin Alpha-1 Legal in Massachusetts? How to Access It Legally

HealthRX.com

Thymosin alpha-1 has no Massachusetts-specific access rule

Print or save as PDF

  • FDA approval / None in the US [1]
  • Orphan designations / Four in the US; not approvals [1]
  • Approved as a medicine in / Italy, India and Hong Kong [1]
  • FDA compounding proposal / Keep it off the pharmacy bulks list [4]
  • Advisory committee vote / 4 yes, 17 no, December 2024 [4]
  • Outsourcing-facility list / Category 3, nominated without adequate support [3]

Does Massachusetts have its own rule for thymosin alpha-1?

Massachusetts-specific access rules for thymosin alpha-1 are not established.

What is thymosin alpha-1's FDA status?

Thymosin alpha-1 (thymalfasin) is a 28-amino-acid peptide with an acetylated N-terminal end, originally isolated from thymosin fraction 5, a thymus extract. The synthetic version with the same sequence is sold outside the US as Zadaxin, a finished 1.6 mg injection that is not interchangeable with bulk peptide powder [1].

It is not FDA-approved: a Drugs@FDA search found no US application, and four US orphan drug designations are not approvals [1]. It is approved as a medicine in some other countries: Italy, where Zadaxin is authorized as an adjuvant to influenza vaccination in immunocompromised people; India, for chronic hepatitis B in adults 18 and older with compensated liver disease and virus replication; and Hong Kong [1].

Can a US pharmacy compound it?

FDA lists thymosin alpha-1 in the "nominated but withdrawn" table on its page about bulk substances that may present significant safety risks. It had been in category 2 and came off when the nominators withdrew it. FDA's concerns remain posted: a significant risk of immunogenicity for certain routes of administration, peptide impurity and characterization problems, and safety information the agency called inadequate to understand the extent of any safety issues [5].

It appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians, updated May 14, 2026 [2]. On the outsourcing-facility list, updated March 21, 2025, it is category 3, "nominated without adequate support" [3]. FDA's category 1 enforcement-discretion policy does not apply to it [2][3].

On December 4, 2024, FDA's Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and the acetate, and FDA proposed that the peptide not be added to the pharmacy bulks list. Members who voted no cited no compelling evidence of clinical effectiveness and safety [4]. It is also not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [6].

What people on Reddit report

These Reddit users discuss where people get thymosin alpha-1 and whether it needs a prescription. They include a patient, a commenter who describes FDA orphan status, and people who ask about legal access.

SoftHeartsSociety · MCAS

You might know this, but I believe you generally have to have it compounded by prescription at least in the US, though I have no idea with other countries :)

A commenter believes US access generally runs through a prescription-based compounded product and suggests asking a compounding pharmacy or a specialist.

Read the source discussion

Junazka · Lyme

Thymosin alpha one i believe got approved by the FDA as an orphan drug for melanoma, or skin cancer. But, good luck trying to get it for something else, off label.

A commenter describes an FDA orphan designation as an approval and says getting it for other uses off label is hard.

Read the source discussion

Questions worth asking

Choose the questions you want to keep

What does the label say to watch for?

There is no US-approved dose [1]. The Italian Zadaxin label, which covers the finished product and not bulk powder, says the product is not for children, is contraindicated in pregnancy and breastfeeding, and calls for caution in people with allergies or autoimmune disease and with other immune-modulating drugs [1].

What is known about harm?

In a 2026 Cochrane review of hepatitis B trials, thymosin alpha-1 may have caused fewer serious adverse events than the comparison treatments (low-certainty evidence); the finding of fewer non-serious events was very low certainty [7].

Is thymosin alpha-1 FDA-approved?
No. A Drugs@FDA search found no US application. Four US orphan drug designations exist, but an orphan designation is not an approval [1].
Can a US compounding pharmacy make thymosin alpha-1?
FDA proposed that it not be added to the pharmacy bulks list, and its Pharmacy Compounding Advisory Committee voted 4 yes to 17 no in December 2024 [4]. On the outsourcing-facility list it is category 3, nominated without adequate support [3].
What dose of thymosin alpha-1 is used?
There is no US-approved dose [1]. The Italian Zadaxin label gives 1.6 mg subcutaneously or intramuscularly twice weekly for four weeks starting at the first vaccination, repeated from week 8 to week 12 at the second vaccination [1].
Show all 9 referencesHide references
Evidence overview for Is Thymosin Alpha-1 Legal in Massachusetts? How to Access It Legally